The FINANCIAL — Boehringer Ingelheim announced the initiation of a Phase 2 clinical trial of BI 764198, an inhibitor of TRPC6, a receptor-operated cation channel. This potent and selective inhibitor of TRPC6 may alleviate the damage to the lung and decrease the risk or severity of acute respiratory complications in patients hospitalized for COVID-19. The aim of therapy with BI 764198 is to reduce the need for ventilator support, to improve patient recovery rate and ultimately to save lives. Boehringer Ingelheim is committed to fighting COVID-19 and contributing with its expertise and resources to develop new therapeutic options for patients…
Read More »
The FINANCIAL — Boehringer Ingelheim announced the initiation of a Phase 2 clinical trial of BI 764198, an inhibitor of TRPC6, a receptor-operated cation channel. This potent and selective inhibitor of TRPC6 may alleviate the damage to the lung and decrease the risk or severity of acute respiratory complications in patients hospitalized for COVID-19. The…
You might be interested in
The FINANCIAL — People with certain inflammatory immune conditions affecting the joints, bowel and skin, such as rheumatoid arthritis, may have…
Epidemiologist explains how to stay on guard against subvariants, noting role of protective measures in transition to new pandemic phase…
A new study measuring the impact of COVID-19 on the wellbeing and mental health of adolescents has found that the…
A federal judge struck down the government’s transportation mask mandate on Monday, making face coverings optional for passengers and employees.…